I'd really need to find that post and let you know but methotrexate is an immunosuppressant as well. The article at the time seemed to broadly state that adding an immunosuppressant might make no difference in terms of preventing antibodies.
Sorry, forgot to say "both standard immunosuppressants - i.e. 6mp/aza" don't work, then MTX is used (which is an immunosuppressant as well, correcT).
MTX, however, works differently than aza and 6mp - the latter two principally work by directly inhibiting DNA/RNA synthesis via purine inhibition. Purine inhibition principally affects fast growing cells - i.e. B-cells and T-cells, while other cells that require the synthesis of DNA and RNA are also affected, but less so. The inhibition for aza and 6mp (aza is a prodrug of 6mp, so basically is 6mp once converted in the body) works because it is a structural analog of certain purines (for people who don't know, purines are making up half of the structural building blocks of both DNA and RNA such as adenine, guanine).
In contrast, MTX principle function is being a competitor to folic acid in blood, as it is a structural analog to folic acid. The consequence of inhibiting the concentration of folic acid is once again the inhibition of DNA/RNA synthesis - but not directly by reducing the amount of available structural building blocks for DNA (not so much RNA) synthesis as folic acid is only required indirectly for cell reproduction, in its function to produce nucleoside thymidine, which is an actual building block of DNA. Plus, folic acid also plays an indirect role in purine synthesis (but does not affect purine synthesis that much as 6mp/aza).
As a result, the difference, broadly speaking, is that MTX has a broader effect on the human metobalism than 6mp/aza which is more targeted on purine inhibitation resulting in both DNA and RNA suppression.
As to the developing antibodies against biologic drugs, that might be so, but adding 6mp/aza to a biologic drug still might make sense as evidenced by several studies (not because adding 6mp/aza is avoiding antibodies, but because of a double attack front - both from inhibiting TNF cytokines growth through the biologics (basically inhibiting the signaling within the body to create more leukocytes which is the target of all biologics) and targeting the leukocyte growth itselve with purine analogues (6mp).